Navigation Links
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:12/16/2009

hase II study evaluating microplasmin in patients with AMD.

The primary endpoint of both of the MIVI-TRUST trials is the non-surgical resolution of focal vitreomacular adhesion after one month. This anatomical endpoint is being measured and recorded using Optical Coherence Tomography (OCT) which provides images that can clearly show the separation of the vitreous from the retina. OCT is a very sensitive and specific method for detecting the resolution of focal vitreomacular adhesion. In addition to the primary endpoint, the Phase III trials will evaluate additional measures of efficacy as well as safety, assessed at various time periods over the six month study period.

It is expected that the results from the first microplasmin Phase III study, the TG-MV-006 study will be presented in Q2 2010 and the results from the TG-MV-007 study in Q3 2010.

Dr. Patrik De Haes, CEO of ThromboGenics commented, "We are very pleased to announce that we have completed enrolment of our second pivotal Phase III trial for microplasmin, ahead of schedule. Microplasmin is key to the success of our ophthalmic focused strategy and the speed at which patients have been recruited is encouraging. We very much look forward to announcing the first results from our MIVI-TRUST Phase III program by mid 2010."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagu
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... For its innovative modular Biomedical Research building ... Scientific has earned a Modular Building Institute (MBI) 2014 ... 30 categories, MBI,s contest is the commercial modular industry,s ... manufacturers, dealers, and product and service providers. ... of our team," said Dan Palmer , President ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... in New York results of AFF008, ... Parkinson,s disease. PD01A is the first therapy against the protein ... The Michael J. Fox Foundation for Parkinson,s Research ... and presented at the press conference on the impact a ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
Breaking Medicine Technology:Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
... JOSE, Calif., June 13, 2011 SI-BONE, Inc. (San Jose, ... of a minimally invasive surgical (MIS) device to treat the ... surgeon training milestone for its iFuse Implant System® with over ... in Europe.  As a result, the medical community,s awareness of ...
... MIAMI, June 13, 2011 Sanomedics International Holdings, Inc. (Pink ... Chairman, with Keith Houlihan, Co-founder and President of Sanomedics ... appointment of Charlie Alvarez, Co-founder and President of Watermark ... "The addition of Charlie to the Sanomedics ...
Cached Medicine Technology:Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 2Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 3Over 400 Surgeons Trained by SI-BONE to Perform Minimally Invasive iFuse Sacroiliac Joint Fusion 4Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 2Mr. Charlie Alvarez Joins the Board of Sanomedics International Holdings, Inc. 3
(Date:7/31/2014)... 2014 Jeremiah’s Tavern ... wood to create a unique atmosphere and highlight ... features reclaimed barn siding on the ... mixed softwoods flowing throughout the interior as flooring. ... sister company New Energy Works Timberframers ...
(Date:7/31/2014)... 31, 2014 US Hair Restoration Founder, Dr. ... be known as Parsa Mohebi Hair Restoration. Since first ... patients in Southern California and around the world, who traveled ... and Orange County. These patients achieved the full benefits of ... that were perfected by Dr. Mohebi. They have come ...
(Date:7/31/2014)... Ce-Classes.com has developed a Learning Management ... to pass inspections and audits. Ce-Classes.com can ... accreditation and state licensing criteria by providing their ... administrators can monitor employee compliance with mandatory training ... can be developed based on the policies and ...
(Date:7/31/2014)... 31, 2014 Current residents at ... program in Flagstaff, AZ, learn to kayak safely for ... and paddle strokes in preparation for next week's wilderness ... think that [the kayaking course] teaches [residents] to listen ... with in their early part of their sobriety," said ...
(Date:7/31/2014)... 31, 2014 Located on one of the ... The Rothenberg Law Firm LLP has moved its office to ... The Rothenberg Law Firm has been handling catastrophic personal injury ... by growth in the firm’s continued success in seeking justice ... York office has a team of experienced and successful trial ...
Breaking Medicine News(10 mins):Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2
... Group to Release Groundbreaking Study on Economic Impact of Life ... State SEATTLE, April 20 An alliance ... launch "We Work for Health," a landmark statewide effort to ... life sciences industry and to promote the growth and success ...
... 20 Stryker Corporation (NYSE: SYK ) reported operating ... Quarter Highlights , , ... basis (2.0% decrease as reported) to $1,601 million , ... constant currency basis (0.2% increase as reported) , ...
... common thread among all 3 conditions , , MONDAY, April ... credence to a long-suspected connection between psoriasis, diabetes and ... the Archives of Dermatology suspect the link ... is associated with all three conditions. , "We were ...
... need to make very difficult choices, such as deciding to ... in the Journal of Consumer Research delves into ... or doctors to make those "tragic choices." , Authors ... Iyengar (both Columbia University) say that from the time of ...
... HCA today announced the recipients of the ... a Physician Assistant at Wesley Medical Center in ... Northside Hospital in Macon, Ga., and Laurence Lesser, ... Center in Snellville. Ga., were honored today during ...
... WASHINGTON, April 20 In a recent study, ... blood into cells that are molecularly and functionally ... that provides a readily accessible source of stem ... cells. The findings were prepublished online in ...
Cached Medicine News:Health News:Life Sciences Leaders to Launch Statewide 'We Work for Health' Economic Development and Jobs Campaign 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Having Psoriasis Raises Risk of Diabetes, Hypertension 2Health News:Tragic choices: Is it better for doctors or patient families to decide? 2Health News:HCA Announces National 2008 Frist Humanitarian Award Recipients 2Health News:HCA Announces National 2008 Frist Humanitarian Award Recipients 3Health News:Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells 2Health News:Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells 3
... absolute knowledge. Access it with ... Diagnostic Workstation, uniting two trusted ... and Orbscan IIz Anterior Segment ... critically important data. Together they ...
... LADARWave® device gives you ... measure and display the ... individual eye. This capability ... a better understanding of ...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
...
Medicine Products: